Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Emergent biosolutions - You Need To See This

3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts

Discover three low P/E small-cap stocks with bullish analyst sentiment and growth potential in a lower interest rate environment

FDA approval of Narcan as over-the-counter drug will boost accessibility, save lives, health officials say

BALTIMORE — As soon as this summer, people will be able to purchase the opioid overdose reversal medication Narcan as easily as they can buy Tylenol and Benadryl, after the U.S. Food and Drug Administration approved it last week to be sold over the counter.

Tribune News Service

Over-the-counter Narcan will save lives, experts say. But the cost will affect access

Over-the-counter Narcan will save lives, experts say. But the cost will affect access

Advisers to the FDA put the opioid overdose-reversal drug a step closer to being sold without a needing a prescription. Even if approved, the medication may not reach many people who need it.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA panel weighs moving opioid antidote over the counter

U.S. health advisers are weighing whether the overdose-reversal drug naloxone should be made available as an over-the-counter medication

The Independent UK

A major drugmaker plans to sell overdose-reversal nasal spray Narcan over the counter

Emergent BioSolutions has applied to the Food and Drug Administration to sell the opioid overdose-reversal drug over the counter. Addiction experts say it may be a key step to lower fentanyl deaths.

The FDA Is Doing Something That Could Actually Cut Overdose Deaths

Naloxone could be available without a prescription by spring.

12 Health Care Stocks Moving In Wednesday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

At concert outside Baltimore plant, musicians protest Maryland pharmaceutical company’s Narcan prices

BALTIMORE — Joined by harm-reduction advocates, local musicians performed outside a Baltimore drug manufacturing facility Wednesday afternoon to protest the price of the overdose-reversing drug Narcan sold by pharmaceutical company Emergent BioSolutions.

Tribune News Service

More than a half billion doses of COVID vaccine made in Baltimore dumped, congressional panel finds

BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response.

Tribune News Service

U.S. FDA Accepts Emergent's Anthrax Vaccine Candidate Filing For Review

U.S. FDA Accepts Emergent's Anthrax Vaccine Candidate Filing For Review

The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ (NYSE: EBS) Biologics License Application (BLA) for its new anthrax vaccine candidate AV7909. The regulatory agency sets the Prescription Drug User Fee Act (PDUFA) goal date for a decision in month of April 2023.

Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract

Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract

Emergent BioSolutions Inc (NYSE: EBS) said Johnson & Johnson (NYSE: JNJ) had breached an agreement by failing to buy the company's minimum quantity of COVID-19 vaccines.

Why Emergent Biosolutions Stock Is Rising Today

Why Emergent Biosolutions Stock Is Rising Today

Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher Monday amid increasing monkeypox concerns.

400 million COVID-19 vaccine doses dumped by Baltimore plant, congressional report finds

BALTIMORE — The Maryland-based vaccine maker Emergent BioSolutions was forced to destroy nearly 400 million doses of COVID-19 vaccine because of potential contamination at its East Baltimore plant, far more than previously known.

Tribune News Service

5 Value Stocks In The Healthcare Sector

5 Value Stocks In The Healthcare Sector

What are Value Stocks?

Get all your
news in one place.

100's of premium titles.
One news app.

Emergent BioSolutions: Q4 Earnings Insights

Emergent BioSolutions (NYSE:EBS) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

1

People

184,401 stories

Carolyn B Maloney

Jennifer Martin

Nabarun Dasgupta

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

Food and Drug Administration

Emergent BioSolutions

Health Catalyst

Kala Pharmaceuticals

Vir Biotechnology

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prescription Drug

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play